ARCHIVES

Perjeta, Herceptin & Docetaxel Combination Extended Survival in HER2-Positive Disease

This article is from The Cancer Letter archive.

Vol. 35 No. 12 | December 28, 2012

Download PDF Visit The Full Archive

Related Articles

NCI disclosure of walk-out by Data and Safety Monitoring Board of the National Lung Screening Trial may be harmful, improper, experts say.

April 16, 2004

NCA Approves Draft of New Outstanding Investigator Grants

February 10, 1984

Hospice Assn. Meeting Planned for April

January 24, 1986

Patients Who Smoke In Treatment Do Worse Than Those Who Quit

March 25, 2011

Frei, Freireich Share One GM Prize; Ames, Erikson Win Others

June 17, 1983

In Brief: Broder Resigns From IVX; Bishop To Receive Public Service Award; Johnston Rejoins NIAID

August 7, 1998